BridgeBio Pharma (NASDAQ:BBIO) executives said the company is focused on sustaining momentum for its newly launched ATTR-CM drug Attruby while preparing for multiple regulatory submissions and potential launches across its genetic disease pipeline over the next 12 months.
Speaking at a Jefferies investor session, Tom Trimarchi, chief financial officer of BridgeBio, said the company is entering a period centered on execution after building a late-stage and commercial portfolio in genetic diseases. He said Attruby is “about a year into the launch” and is still ramping, with U.S. sales annualizing at about $720 million. Trimarchi also cited strong uptake outside the U.S. through BridgeBio’s partner Bayer.
Attruby Gains First-Line Share
Jefferies analyst Andrew Tsai noted that Attruby has captured more than 25% first-line market share despite not being first to market. Trimarchi said the company’s differentiation message centers on the drug’s potency as a TTR stabilizer and clinical trial results summarized by the company as “3-42-50”: three months to separation, a 42% reduction in overall survival events and a 50% reduction in hospitalization events.
Trimarchi said physicians are increasingly choosing Attruby because they view it as differentiated. He said BridgeBio is continuing to publish data in subpopulations and expects real-world evidence to be important in providing a more contemporary comparison with tafamidis.
BridgeBio reported $180 million in first-quarter sales, up from $145 million in the prior quarter. Trimarchi said the company did not see unusual first-quarter seasonality in converting demand to sales. He said average weekly new starts continue to improve, driven by both share gains in the frontline setting and market expansion. Trimarchi said the company previously estimated 2,000 to 3,000 treatment-naive patients were entering the funnel each quarter, but that now appears closer to 3,000 to 4,000.
Asked whether Attruby’s peak first-line share could exceed prior expectations, Trimarchi said BridgeBio continues to view 30% to 40% as the right peak range based on market research, though he said the company hopes to push higher.
Pipeline Programs Move Toward Regulatory Milestones
For encaleret, a company representative said BridgeBio submitted its new drug application in May for ADH1 and does not expect an advisory committee meeting, citing the risk-benefit profile from the Phase 3 data set. The representative said population genetics databases suggest about 10,000 to 12,000 ADH1 patients in the U.S., while claims data show about 2,000 patients had been identified as of the end of 2025. The representative said claims data show about 70 new patients per month on average.
Trimarchi said BridgeBio is working ahead of launch to confirm diagnoses and ensure patients have appropriate genetic confirmation. The company representative said BridgeBio would be prepared to launch soon after a potential PDUFA date, while noting that adoption would depend partly on how frequently patients see specialists.
BridgeBio also plans to begin a Phase 3 study of encaleret in chronic hypoparathyroidism this summer. The company representative said the study is expected to run for six months and could enroll more quickly than the ADH1 study because the broader patient population is easier to identify. The representative said BridgeBio plans to emphasize 24-hour urine calcium in the primary endpoint, describing it as an important surrogate for renal health.
LGMD and Achondroplasia Programs Highlight Rare Disease Expansion
Trimarchi said BBP-418 for limb-girdle muscular dystrophy Type 2I/R9 addresses a significant unmet need and could be the first drug for that market. He estimated prevalence at about 7,000 patients across the U.S. and Europe, with roughly 2,000 to 3,000 in the U.S. He said many patients know they have muscular dystrophy or limb-girdle muscular dystrophy, but BridgeBio needs to drive more complete genetic diagnosis to identify the 2I/R9 population.
Trimarchi said BridgeBio expects a priority review voucher if BBP-418 is approved. He added that the company is also pursuing studies in LGMD 2U and 2M, broader pediatric populations and Fukuyama muscular dystrophy, though the Fukuyama path will require additional regulatory work.
For infigratinib in achondroplasia, Trimarchi said BridgeBio expects to submit an NDA in the second half of the year. He said he would not expect an advisory committee, though the company will know more after the FDA’s 60-day review. Trimarchi said the oral therapy is differentiated by convenience and by data suggesting effects beyond height, including proportionality.
Trimarchi said the achondroplasia market includes both potential switches from injectable therapies and treatment-naive patients. He said existing injectable products remain under-penetrated in the U.S., and BridgeBio’s task will be to both move patients from injectables and expand the treated market with an oral option.
Across the portfolio, Trimarchi said BridgeBio’s priorities are to keep growing Attruby, continue gaining first-line share and secure approvals for the company’s next three drugs “on time” and with labels that allow the company to deliver them to patients.
About BridgeBio Pharma (NASDAQ:BBIO)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
